← Back to Search

RelieVRx for Opioid Use Disorder

N/A
Waitlist Available
Led By Hector Perez, MD, MS
Research Sponsored by Albert Einstein College of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
English proficiency
chronic pain of at least moderate pain severity (score ≥4 on the Pain, Enjoyment of Life, and General Activity (PEG) scale)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3 weeks, 6 weeks
Awards & highlights

Study Summary

This trial tests a VR device to help people w/ chronic pain & opioid addiction.

Eligible Conditions
  • Opioid Use Disorder
  • Chronic Pain

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You must be able to speak and understand English.
Select...
You experience ongoing, moderate to severe pain (rated 4 or higher on the PEG scale).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3 weeks, 6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3 weeks, 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Opioids
Change in Pain Intensity
Percent of participants contacted that are enrolled
Secondary outcome measures
Anxiety
Change in Cognitive Function
Mental Depression
+6 more
Other outcome measures
Hydrocortisone
Change in Serum C-reactive Protein
Change in Serum Cortisol
+2 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: RelieVRxActive Control1 Intervention
RelieVRx was designed for at-home use and comes with a sequence of daily immersive experiences. Participants in the intervention group will complete 20-30 minute VR sessions twice per week over the course of 6 weeks.
Group II: Sham Virtual RealityPlacebo Group1 Intervention
The sham virtual reality (VR) device is also by RelieVRx. However, it lacks the immersive nature of the interventional VR. Control participants will complete 20-30 minute VR sessions twice per week over the course of 6 weeks.

Find a Location

Who is running the clinical trial?

Albert Einstein College of MedicineLead Sponsor
285 Previous Clinical Trials
11,854,624 Total Patients Enrolled
Hector Perez, MD, MSPrincipal InvestigatorAlbert Einstein College of Medicine

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research specifically looking for new participants?

"Affirmative. According to the information accessible on clinicaltrials.gov, this clinical trial is currently enrolling participants with an initial posting date of February 8th 2023 and a recent update taking place on February 9th 2023. 40 volunteers are required from 1 medical facility."

Answered by AI

What are the major goals of this trial?

"The goal of this clinical trial, which will be monitored over the course of 6 weeks and beginning at baseline, is to measure Change in Pain Intensity. Secondary objectives include evaluating change in Pain Interference (measured with a Patient-Reported Outcomes Measurement Information System Pain Intensity Subscale), measuring Change in Fatigue (assessed by a Patient-Reported Outcomes Measurement Information Fatigue 4a Heal) and examining Changes in Social Function (via the use of the Patient-Reported Outcomes Measurement Information Ability to Participate Social 4a Heal)."

Answered by AI

What is the current patient count for this clinical trial?

"Affirmative, the information on clinicaltrials.gov suggests that this trial is actively enrolling participants at present. The initial posting was made on 8th February 2023 and revised 9th February 2023. Forty individuals across one medical site are being sought after for the study."

Answered by AI
~9 spots leftby Mar 2025